多西他赛联合洛铂治疗蒽环类耐药的晚期乳腺癌疗效分析

Clinical observation of docetaxel plus lobaplatin in treating anthracyclines resistant advanced breast cancer

目的:观察多西他赛联合洛铂方案对蒽环类耐药的晚期乳腺癌患者的临床疗效及毒副作用。方法:采用多西他赛联合洛铂方案治疗晚期乳腺癌患者42例。多西他赛75mg/m2静脉滴注第1天,洛铂30mg/m2静脉滴注第1天。每21天重复,至少应用2个周期。结果:42例患者中,CR、PR分别为4、19例,总有效率为54.8%(23/42),1年生存率为64.3%(27/42),主要不良反应为骨髓抑制。结论:多西他赛联合洛铂方案治疗蒽环类耐药的晚期乳腺癌疗效好,不良反应轻,是治疗蒽环类耐药的晚期乳腺癌较好的方案。

Objective：To observe the curative effect and toxicity of docetaxel plus lobaplatin in advanced breast cancer patients who were drug fast in using anthracene nucleus drugs.Methods：Forty two female patients received docetaxel 75mg/m2 on dl and lobaplatin 30mg/m2 on d1 of every 21 days.Every patient was administered at least 2 cycles.Results：Four patients achieved complete response and 19 partial response,the overall response rate was 54.8%,one year survival rate was 64.2%,the main side effect was marrow surpression.Conclusion：Combined chemotherapy of docetaxel and lobaplatin has a good anti-tumor activity and manageable toxicity on advanced breast cancer patients who were drug fast in using anthracene nucleus drugs.